Bladder Cancer Clinical Trials
Here are the 6 most popular medical studies for bladder cancer
Tyrosine Kinase Inhibitor
Erdafitinib for Bladder Cancer
This trial will compare recurrence-free survival rates for patients with high-risk bladder cancer who have FGFR mutations or fusions and have had a recurrence after BCG therapy, between those who receive erdafitinib and those who receive the investigator's choice of standard therapy.
Popular filter options for bladder cancer trials
Metastatic Bladder Cancer Clinical Trials
View 97 metastatic bladder cancer medical studies.
Antibody-drug conjugate
Enfortumab Vedotin for Bladder Cancer
“ I have had 3 6 week treatments 1st was BCG, second was Gemcitabine and Taxotere as was the 3rd which finished in April. Now they do not want to treat me any longer here in Ohio.”
Monoclonal Antibodies
Pembrolizumab/Vibostolimab Co-Formulation for Solid Tumors
“ My mother in law is having an advanced metastatic cancer of an endometrial origin. She is currently struggling with RBC’s count so I was not sure if this means her organs are functional (hence my reply with ‘unsure’).”
Virtual Histology for Bladder Cancer
This trial is testing a new way to use MRI to look for bladder cancer. A contrast agent is used to help better visualize the tumor. The MRI images are then reviewed by two radiologists to determine the stage of the cancer.
PD-1 Positive Clinical Trials
View 19 PD-1 positive medical studies.
Monoclonal Antibodies
Pembrolizumab/Vibostolimab Co-Formulation for Solid Tumors
“ My mother in law is having an advanced metastatic cancer of an endometrial origin. She is currently struggling with RBC’s count so I was not sure if this means her organs are functional (hence my reply with ‘unsure’).”
Monoclonal Antibodies
TAR-200 + Cetrelimab for Bladder Cancer
This trial is testing TAR-200, a new immunotherapy drug, for bladder cancer. TAR-200 will be tested alone and in combination with cetrelimab, another immunotherapy drug, to see if it is effective in treating bladder cancer.
Antibody-Drug Conjugate
Enfortumab Vedotin + Other Therapies for Urothelial Cancer
This trial will test an experimental drug, enfortumab vedotin, either alone or in combination with other cancer treatments. Pembrolizumab is a checkpoint inhibitor that is used to treat patients with urothelial cancer--a type of cancer that includes bladder, renal pelvis, ureter, or urethra cancer. The study will examine the side effects of enfortumab vedotin and measure if the cancer shrinks with different treatment combinations.
Monoclonal Antibodies
Pembrolizumab + Entinostat for Bladder Cancer
This trial is testing a new cancer treatment combining immunotherapy with a class I HDAC inhibitor. The goal is to see if the treatment changes immunogenomic markers in patients with muscle-invasive bladder cancer who are ineligible for cisplatin-based neoadjuvant chemotherapy.
Procedure
UGN-201 for Bladder Cancer
This trial is studying the safety of a drug called UGN-201 in people with bladder cancer who are having surgery. The side effects of the drug and any complications from surgery will be monitored. The study will also look at how well the drug works in downgrading the cancer and at changes in biomarkers in response to the drug.
PD-L1 Positive Clinical Trials
View 18 PD-L1 positive medical studies.
Monoclonal Antibodies
Pembrolizumab/Vibostolimab Co-Formulation for Solid Tumors
“ My mother in law is having an advanced metastatic cancer of an endometrial origin. She is currently struggling with RBC’s count so I was not sure if this means her organs are functional (hence my reply with ‘unsure’).”
Antibody-Drug Conjugate
Enfortumab Vedotin + Other Therapies for Urothelial Cancer
This trial will test an experimental drug, enfortumab vedotin, either alone or in combination with other cancer treatments. Pembrolizumab is a checkpoint inhibitor that is used to treat patients with urothelial cancer--a type of cancer that includes bladder, renal pelvis, ureter, or urethra cancer. The study will examine the side effects of enfortumab vedotin and measure if the cancer shrinks with different treatment combinations.
Monoclonal Antibodies
Pembrolizumab + Entinostat for Bladder Cancer
This trial is testing a new cancer treatment combining immunotherapy with a class I HDAC inhibitor. The goal is to see if the treatment changes immunogenomic markers in patients with muscle-invasive bladder cancer who are ineligible for cisplatin-based neoadjuvant chemotherapy.
Procedure
UGN-201 for Bladder Cancer
This trial is studying the safety of a drug called UGN-201 in people with bladder cancer who are having surgery. The side effects of the drug and any complications from surgery will be monitored. The study will also look at how well the drug works in downgrading the cancer and at changes in biomarkers in response to the drug.
Phase 3 Bladder Cancer Clinical Trials
View 97 phase 3 bladder cancer medical studies.
Monoclonal Antibodies
Pembrolizumab + Chemoradiotherapy for Bladder Cancer
This trial will compare the effectiveness of a new cancer treatment (pembrolizumab + chemoradiotherapy) to the current standard of care (chemoradiotherapy alone) for people with muscle-invasive bladder cancer.
Chemotherapy
Chemotherapy + Immunotherapy for Bladder Cancer
This trial will compare the efficacy of nivolumab plus neoadjuvant gemcitabine/cisplatin chemotherapy followed by post-surgery continuation of immuno-oncology therapy versus neoadjuvant gemcitabine/cisplatin chemotherapy alone in adult participants with previously untreated muscle-invasive bladder cancer.
Monoclonal Antibodies
TAR-200 + Cetrelimab for Bladder Cancer
This trial will compare the effectiveness of two treatments for bladder cancer. One treatment is TAR-200 in combination with cetrelimab, and the other is concurrent chemoradiotherapy. The goal is to see which treatment leads to better BI-EFS (bladder cancer free survival).
Immunotherapy
BCG + N-803 for Bladder Cancer
This trial is testing a new drug, N-803, for people with bladder cancer that has not responded to BCG treatment. Patients will receive the new drug through a urinary catheter weekly for 6 weeks, followed by maintenance treatment every 3 or 6 weeks for up to 3 years.
Monoclonal Antibodies
Durvalumab + Tremelimumab + Chemotherapy for Bladder Cancer
This trial is studying if adding the drugs durvalumab and tremelimumab to standard chemotherapy can help to control transitional cell carcinoma of the urothelium that has spread to other parts of the body and cannot be removed by surgery.
Bladder Cancer Clinical Trials With No Placebo
View 97 bladder cancer medical studies that do not have a placebo group.
Antibody-drug conjugate
Enfortumab Vedotin for Bladder Cancer
“ I have had 3 6 week treatments 1st was BCG, second was Gemcitabine and Taxotere as was the 3rd which finished in April. Now they do not want to treat me any longer here in Ohio.”
Monoclonal Antibodies
Pembrolizumab/Vibostolimab Co-Formulation for Solid Tumors
“ My mother in law is having an advanced metastatic cancer of an endometrial origin. She is currently struggling with RBC’s count so I was not sure if this means her organs are functional (hence my reply with ‘unsure’).”
Virtual Histology for Bladder Cancer
This trial is testing a new way to use MRI to look for bladder cancer. A contrast agent is used to help better visualize the tumor. The MRI images are then reviewed by two radiologists to determine the stage of the cancer.
View More Bladder Cancer Trials
See another 69 many medical studies focused on bladder cancer.
Frequently Asked Questions
Introduction to bladder cancer
What are the top hospitals conducting bladder cancer research?
Bladder cancer, a condition that affects thousands of individuals across the country, has prompted top hospitals to spearhead clinical trials in search of innovative treatments and improved outcomes. In Myrtle Beach, the Carolina Urologic Research Center has taken charge with an impressive ten active bladder cancer trials and a total of 29 trials conducted to date. Since their first recorded bladder cancer trial in 2007, this dedicated center has been committed to advancing research and patient care. Not far away, Memorial Sloan Kettering Cancer Center in New York City stands as another prominent institution making strides in the field. With nine ongoing bladder cancer trials and a history of 33 completed studies since their inaugural trial in 2004, they are at the forefront of groundbreaking discoveries.
In Saint Louis at Washingtonn New York City stands as another prominent institution making strides in the field. With nine ongoing bladder cancer trials and a history of 33 completed studies since their inaugural trial in 2004, they are at the forefront of groundbreaking discoveries.
In Saint Louis at Washington University School of Medicine, researchers have undertaken six active clinical trials for bladder cancer, building on their expertise from conducting 20 previous studies since they began investigating this disease in 2005. Meanwhile, Northwestern University located in Chicago is also contributing significantly with its own set of six ongoing bladder cancer trials while having accomplished 14 prior investigations since starting their pioneering work relatively recently in2012.The Moffitt Cancer Center situated in Tampa may seem smaller-scale by comparison but plays an equally vital role within the medical community; it currently hosts six active clinical tests specifically focusing on bladder cancers following twenty-one earlier experiments which commenced only ten years agoin2010.
Through these select institutions' dedication and unwavering commitment to finding effective treatments for bladder cancer patients, hope is kindled for those affected by this challenging condition around the nation. As each new trial pushes boundaries and uncovers potential breakthroughs towards conquering this disease altogether,it marks a step closer toward offering brighter horizons for countless individuals grappling with such diagnosis globally
Which are the best cities for bladder cancer clinical trials?
When it comes to bladder cancer clinical trials, several cities have emerged as leading hubs for research and development. New York City tops the list with 50 active trials investigating treatments like Pembrolizumab, Enfortumab vedotin, and Nivolumab. Following closely behind is Los Angeles, California, with 36 ongoing studies focusing on pharmacological approaches such as TAR-200 + Cetrelimab and UGN-102. Nashville, Tennessee also stands out with 26 active trials exploring options like TAR-200 and Sapanisertib. Boston, Massachusetts, California, with 36 ongoing studies focusing on pharmacological approaches such as TAR-200 + Cetrelimab and UGN-102. Nashville, Tennessee also stands out with 26 active trials exploring options like TAR-200 and Sapanisertib. Boston, Massachusetts follows suit with 25 trials examining Sapanisertib, Cobimetinib, and Nivolumab. Lastly, Atlanta, Georgia offers individuals access to 21 active trials studying treatments including enfortumab vedotin (EV) and Genistein. These cities serve as important centers for advancing bladder cancer care through cutting-edge clinical research efforts.
Which are the top treatments for bladder cancer being explored in clinical trials?
Bladder cancer research is advancing rapidly, with several promising treatments currently being explored in clinical trials. Leading the pack is pembrolizumab, a groundbreaking drug that has caught the attention of researchers through its involvement in seven active bladder cancer trials. Since its introduction in 2015, it has amassed an impressive 43 all-time clinical trials dedicated to fighting this disease. Close behind is nivolumab, another notable contender with five ongoing trials and 26 all-time bladder cancer studies since its debut in 2015. Atezolizumab also shows great promise, participating in four active and 19 all-time clinical trials for bladder cancer since it was first listed back in 2014. Additionally, enfortumab vedotin and erdafitinib are making strides with three active trials each and showing encouraging potential as effective treatments for this challenging condition. As these innovative therapies continue to undergo rigorous investigation, hope grows stronger for improved outcomes among patients battling bladder cancer worldwide
What are the most recent clinical trials for bladder cancer?
Exciting advancements in bladder cancer research have led to several recent clinical trials that hold promise for patients. Among these trials is TARA-002, which has progressed to Phase 1 and Phase 2 stages, displaying encouraging results. Another trial focuses on Transurethral Resection of Bladder Tumor as a potential treatment option for bladder cancer, with Phase 1 findings showing positive outcomes. Additionally, the use of sacituzumab govitecan in Phase 2 studies demonstrates its potential efficacy in combating bladder cancer. The TARA-002 trial also shows promise in early-stage development (Phase 1), while a separate study explores the benefits of IO102-IO103 and pembrolizumab combination therapy in treating this aggressive disease. These remarkable clinical trials offer hope and new possibilities for individuals battling bladder cancer.
What bladder cancer clinical trials were recently completed?
Recently concluded clinical trials have made significant strides in the field of bladder cancer, offering new hope for patients. Among them, Vaxiion Therapeutics' trial on VAX014 concluded in May 2019, while Nektar Therapeutics completed their study on Bempegaldesleukin in April 2019. Furthermore, PrECOG's investigation into the combination therapy Nivolumab/Lirilumab reached completion in March 2019. These advancements showcase the tireless efforts of researchers and encourage optimism for improved treatments against bladder cancer.